SolasCure key facts
as of Oct 2026- Developer of hydrogel designed to treat patients with chronic wounds.
- SolasCure is valued at approximately $57.0M as of Oct 2026 (last reported valuation).
- It has raised $34.2M; the latest was Later Stage VC in Apr 2025.
- Notable investors include Innovate UK, European Innovation Council, Texas Medical Center, SyndicateRoom, Development Bank of Wales — 17 tracked in total.
- Status: Privately Held (backing).
SolasCure's last reported valuation, Jan 2021. Nothing priced has surfaced since.
- ·The complete investor list: 17 names
- ·Watch SolasCure: the Monday email on marks, rounds and moves
SolasCure funding rounds
No funding rounds for SolasCure are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs SolasCure
17+SolasCure valuation
SolasCure's last reported valuation was $57 million in Jan 2021. No priced round, secondary trade or fund mark has surfaced since.
SolasCure investors
17 investors are on record for SolasCure, including Innovate UK, European Innovation Council, Texas Medical Center and SyndicateRoom. By type, the record holds 4 venture capital firms and 1 family office.
About SolasCure
Developer of hydrogel designed to treat patients with chronic wounds. The company's hydrogel contains a recombinant enzyme derived from maggots which aims to accelerate wound debridement, enabling patients to improve the outcomes in all settings and accelerate wound cleaning.
- Sector
- Healthcare
- HQ
- Cambridge, United Kingdom
- Founded
- 2017
- Employees
- 22
- Website
- solascure.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.